case_images: PMC10653709_01
case_images: Chest X-ray during chemotherapy chest X-ray showing the lungs at the initiation of osimertinib therapy at 13 months (a), appearance of pneumothorax at 18 months (b), enlargement of the cysts with osimertinib withdrawal at 19 months (c), and disappearance of the cysts after four cycles of second-line therapy at 22 months (d).
case_images: cro-2023-0016-0001-534711_F01.jpg
case_images: PMC10653709_01_cro-2023-0016-0001-534711_F01.jpg
case_images: F1
case_images: Chest X-ray (Fig. 1) and CT scan (Fig. 2) showed right-sided pneumothorax and multiple bilateral thin-walled (<4 mm thick) cysts without nodules, respectively. One month after osimertinib discontinuation, the number and size of the lung cysts continued to increase (Fig. 1c). All diffuse lung cysts markedly decreased in size after chemotherapy initiation, while some disappeared, as shown by chest X-ray and CT scans (Fig. 1d, 2c).
case_images: CT scan during chemotherapy CT scan showing the baseline before the initiation of osimertinib (a), the presence of a nodule in the left upper lobe of the lung at 13 months from the initiation of osimertinib therapy (b), the appearance of pneumothorax and diffuse cysts at 18 months (c), and the disappearance of the cysts after four cycles of second-line therapy at 22 months (d). CT, computed tomography.
case_images: cro-2023-0016-0001-534711_F02.jpg
case_images: PMC10653709_01_cro-2023-0016-0001-534711_F02.jpg
case_images: F2
case_images: All diffuse lung cysts markedly decreased in size after chemotherapy initiation, while some disappeared, as shown by chest X-ray and CT scans (Fig. 1d, 2c).
case_images: Dynamic monitoring of CEA and its timeline serum CEA levels indicate the clinical response of the initial treatment, disease progression, and second line of therapy. CEA, carcinoembryonic antigen.
case_images: cro-2023-0016-0001-534711_F03.jpg
case_images: PMC10653709_01_cro-2023-0016-0001-534711_F03.jpg
case_images: F3
case_images: Laboratory tests revealed an increase in serum CEA levels (252.7 ng/mL) (Fig. 3).